Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

被引：0
|
作者：
Makoto Ueno
Masafumi Ikeda
Takashi Sasaki
Fumio Nagashima
Nobumasa Mizuno
Satoshi Shimizu
Hiroki Ikezawa
Nozomi Hayata
Ryo Nakajima
Chigusa Morizane
机构：
[1] Kanagawa Cancer Centre Hospital,Department of Hepatobiliary and Pancreatic Oncology
[2] National Cancer Center Hospital East,undefined
[3] Cancer Institute Hospital of JFCR,undefined
[4] Kyorin University,undefined
[5] Aichi Cancer Centre Hospital,undefined
[6] Saitama Cancer Centre,undefined
[7] Eisai Co. Ltd.,undefined
[8] Eisai Inc.,undefined
[9] National Cancer Centre Hospital,undefined
来源：
BMC Cancer | / 20卷
关键词：
Lenvatinib; Biliary tract cancer; Cholangiocarcinoma; Gallbladder cancer; Ampulla of Vater;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Yi, Seong Yoon
    Park, Young Suk
    Kim, Hyo Song
    Jun, Hyun Jung
    Kim, Kyoung Ha
    Chang, Myung Hee
    Park, Min Jae
    Uhm, Ji Eun
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1141 - 1145
  • [42] Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors
    Schweitzer, Nora
    Kirstein, Martha M.
    Kratzel, Anna-Maria
    Mederacke, Young-Seon
    Fischer, Mareike
    Manns, Michael P.
    Vogel, Arndt
    LIVER INTERNATIONAL, 2019, 39 (05) : 914 - 923
  • [43] SECOND-LINE CHEMOTHERAPY IN ADVANCED BILIARY TRACT CANCER: A RETROSPECTIVE SERIES
    Brungs, Daniel
    Aghmesheh, Morteza
    Sjoquist, Katrin
    Goldstein, David
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 168 - 168
  • [44] Response to letter 'Outcome of second-line chemotherapy for biliary tract cancer'
    Walter, Thomas
    Horgan, Anne M.
    McNamara, Mairead
    McKeeve, Liz
    Min, Trisha
    Hedley, David
    Serra, Stefano
    Krzyzanowska, Monika K.
    Chen, Eric
    Mackay, Helen
    Feld, Ronald
    Moore, Malcolm
    Knox, Jennifer J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1512 - 1513
  • [45] SECOND-LINE CHEMOTHERAPY BY FOLFIRINOX WITH UNRESECTABLE PANCREATIC CANCER (PHASE I, II STUDY)
    Kobayashi, N.
    Shimamura, T.
    Tokuhisa, M.
    Goto, A.
    Endo, I.
    Ichikawa, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [46] Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Myung Hwan Rho
    Suee Lee
    Young Suk Park
    Joon Oh Park
    Eun Mi Nam
    Hyo Rak Lee
    Hyun Jung Jun
    Kyong-Choun Chi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 757 - 762
  • [47] Second-line chemotherapy by FOLFIRINOX with unresectable pancreatic cancer (phase I, II study)
    Kobayashi, Noritoshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Endo, Itaru
    Ichikawa, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [48] Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Rho, Myung Hwan
    Lee, Suee
    Park, Young Suk
    Park, Joon Oh
    Nam, Eun Mi
    Lee, Hyo Rak
    Jun, Hyun Jung
    Chi, Kyong-Choun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 757 - 762
  • [49] Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
    Park, Chan Su
    Sung, Min Je
    Kim, So Jeong
    Jo, Jung Hyun
    Lee, Hee Seung
    Chung, Moon Jae
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    Park, Jeong Youp
    CANCERS, 2022, 14 (17)
  • [50] Treatment of Primary Biliary Cholangitis First-Line and Second-Line Therapies
    Liu, Chung-Heng
    Bowlus, Christopher L.
    CLINICS IN LIVER DISEASE, 2022, 26 (04) : 705 - 726
12345